FIA
RVMD icon

FNY Investment Advisers’s Revolution Medicines RVMD Stock Holding History

FNY Investment Advisers’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,310
Closed -$191K – 1030
2026
Q1 		$127K Buy
+1,310
New +$132K 0.06% 249
2025
Q4 		– Sell
-2,365
Closed -$110K – 1396
2025
Q3 		$110K Buy
+2,365
New +$92.6K 0.04% 368

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

FNY Investment Advisers's RVMD Position: Q2 2026 in Review

FNY Investment Advisers sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 1,310 shares — an estimated $191K sold.

FNY Investment Advisers first reported a position in RVMD in Q3 2025 and held it in 2 quarters. The position peaked at $127K in Q1 2026. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • FNY Investment Advisers reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 1,310 Revolution Medicines shares in Q2 2026, an estimated $191K.
  • FNY Investment Advisers first reported a position in Revolution Medicines in Q3 2025 and held it in 2 quarters.
  • FNY Investment Advisers's Revolution Medicines position peaked at $127K in Q1 2026.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.